Moving forward: Implementing health psychology research to improve patient acceptance of biosimilars
Author:
Publisher
Elsevier BV
Subject
Pharmaceutical Science,Pharmacy
Reference57 articles.
1. Medicine use and spending in the U.S.: a review of 2017 and outlook to 2022;IQVIA,2018
2. Uptake of infliximab biosimilars among the medicare population;Chen;JAMA Intern Med,2020
3. Current perspectives on biosimilars;Agbogbo;J Ind Microbiol Biotechnol,2019
4. Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries?;Kim;Front Pharmacol,2020
5. Utilization and treatment costs of tumor necrosis factor inhibitors after the introduction of biosimilar infliximab in the United States;Kim;Arthritis Rheumatol,2020
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar;ACR Open Rheumatology;2023-11-23
2. Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto;Clinical Rheumatology;2023-11-21
3. 炎症性腸疾患専門外来における薬剤師外来の有用性の検討;YAKUGAKU ZASSHI;2023-11-01
4. Patients’ Perceptions of Biosimilars: A Systematic Review;BioDrugs;2023-09-07
5. Trust in the approval process of medicines mediates the effect of an educational intervention on the pain relief induced by a generic analgesic;Research in Social and Administrative Pharmacy;2023-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3